Ivonescimab plus chemotherapy reports overall survival benefit in trial
SMMT said Ivonescimab plus chemotherapy showed a statistically significant overall survival benefit versus durvalumab plus chemotherapy in first-line advanced biliary tract cancer in a single-region trial in China.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.